-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For skin diseases of dermatomyositis, treatment options are limited
The study was conducted between July 2015 and August 2017 and included participants with ≥ age 18 years, ≥14 by cutaneous dermatomyositis disease area and severity index of activity, and subjects who failed or were intolerant to hydroxychloroquine treatment had at least moderate activity of dermatomyositis skin activity
Participants received 20 mg of Lenabasum per day for 28 days, then 20 mg twice daily for 56 days or received a placebo
As a result, a total of 22 subjects were randomly assigned to lenabasum (n = 11) or placebo (n = 11
In summary, the findings suggest that Lenabasum treatment is well tolerated and is associated
Original Source:
Victoria P Werth, et al.